-
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial: A prospective multicenter trial
van Kempen, Z. L. E., Hoogervorst, E. L. J., Wattjes, M. P., Kalkers, N. F., Mostert, J. P., Lissenberg-Witte, B. I., de Vries, A., ten Brinke, A., van Oosten, B. W., Barkhof, F., Teunissen, C. E., Uitdehaag, B. M. J., Rispens, T. & Killestein, J., 11 Aug 2020, In: Neurology. 95, 6, p. e745-e754Research output: Contribution to journal › Article* › Academic › peer-review
-
Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ)
van Munster, C. E. P., Kaya, L., Obura, M., Kalkers, N. F. & Uitdehaag, B. M. J., 2019, In: Multiple sclerosis (Houndmills, Basingstoke, England). 26, 4, p. 505-508 4 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS
Eikelenboom, M. J., Killestein, J., Izeboud, T., Kalkers, N. F., Baars, P. A., van Lier, R. A. W., Barkhof, F., Uitdehaag, B. M. J., Polman, C. H. & van Lier, R., 2005, In: Journal of neuroimmunology. 158, 1-2, p. 222-230Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
